Not a member yet? Register here
Ivosidenib plus azacitidine for patients with IDH1-mutated acute myeloid leukaemia
Zanubrutinib as a new treatment option for patients with Waldenström macroglobulinaemia
FDA approval for brentuximab vedotin for children with high-risk Hodgkin lymphoma
Amsterdam scientists investigate why immunotherapy fails in Chronic Lymphocytic Leukaemia
New haematology reimbursement in Belgium: polatuzumab vedotin▼ (Polivy®) for previously unt...
Rondaptivon pegol can be used as a treatment for severe and nonsevere haemophilia A
Index latest issue
Highlights in multiple myeloma
Highlights in myeloproliferative neoplasms
Highlights in aggressive lymphoma
Highlights in indolent lymphomas and chronic lymphocytic leukaemia
Highlights in acute myeloid leukaemia
Highlights in myelodysplastic syndromes
New haematology reimbursements in Belgium
Upcoming scientific event: “bringing immunoscience to the clinic”
Oral decitabine–dedazuridine for myelodysplastic syndromes and chronic myelomonocytic leukae...
MRD-guided ibrutinib and venetoclax regimen improves PFS in CLL patients
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic ...
BJH offers you the opportunity to stay informed of the latest developments in the field of Hematology
Canakinumab in children and young adults with sickle cell anaemia
Long-term remission rates after treatment with tisagenlecleucel in paediatric and young adult ...
Encouraging results with loncastuximab tesirine plus rituximab for DLBCL patients
New Danish app helps doctors in making better decisions for leukaemia patients